TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10638607

Group type: EXPERIMENTAL
Intervention: Combined radiation therapy (RT) and chemotherapy (50 Gy in 25 fractions over 5 weeks, plus cisplatin 75 mg/m2 i.v. on specific weeks, and continuous infusion fluorouracil (5FU) 1 g/m2 per day for the first 4 days of the same weeks)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Radiation therapy (RT) alone (64 Gy in 32 fractions over 6.4 weeks)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy plus esophagectomy (three cycles of preoperative cisplatin and 5FU, two cycles after operation for responding patients)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Esophagectomy alone
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Chemotherapy (cisplatin and 5FU)
Number of subjects: 440
Study: 8842665

Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg
Number of subjects: 60
Study: 1736753

Group type: EXPERIMENTAL
Intervention: Clonidine 0.2 mg orally at bedtime
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control nights (placebo)
Number of subjects: 8
Study: 3859828

Group type: EXPERIMENTAL
Intervention: Modified Rinn Snap‐A‐Ray film‐holding device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Rinn Snap‐A‐Ray film‐holding device
Number of subjects: 0
Study: 31371144

Group type: EXPERIMENTAL
Intervention: VRRS‐Tablet (experimental linguistic treatment)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional linguistic treatment (control)
Number of subjects: 30
Study: 29504321

Group type: EXPERIMENTAL
Intervention: Ultrasound guided subcostal TAP block with 0.375% bupivacaine (20ml volume) on each side of the abdomen
Number of subjects: 126

Group type: COMPARATOR
Intervention: Ultrasound guided posterior TAP block with 0.375% bupivacaine (20ml volume) on each side of the abdomen
Number of subjects: 126
Study: 27494996

Group type: EXPERIMENTAL
Intervention: Intraumbilical incision (IU)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Periumbilical incision (PU)
Number of subjects: 130
Study: 24699894

Group type: EXPERIMENTAL
Intervention: Sucroferric oxyhydroxide 1 g
Number of subjects: 0
Study: 22967202

Group type: EXPERIMENTAL
Intervention: Internet-based self-help problem solving treatment (PST)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 166
Study: 20573795

Group type: EXPERIMENTAL
Intervention: Yogurt with a vegetable-oil emulsion
Number of subjects: 16

Group type: COMPARATOR
Intervention: Equal-calorie control product
Number of subjects: 16
Study: 18632543

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 62
Study: 16891444

Group type: EXPERIMENTAL
Intervention: Methionine loading
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14516228

Group type: EXPERIMENTAL
Intervention: Self‐performed tasks (SPTs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Experimenter‐performed tasks (EPTs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Categorized lists
Number of subjects: 0
Study: 10834665

Group type: EXPERIMENTAL
Intervention: Serum SLPI in septic surgical patients (132+/‐15 ng/mL)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Serum SLPI in healthy adults after lipopolysaccharide administration (50.2+/‐4.0 ng/mL)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Correlation of serum SLPI with organ dysfunction
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Recombinant human SLPI in vitro
Number of subjects: 7
Study: 8800103

Group type: COMPARATOR
Intervention: Group I: No precordial ST segment depression (n = 346)
Number of subjects: 1321

Group type: COMPARATOR
Intervention: Group II: ST segment depression in leads V1 to V3 greater than in leads V4 to V6 (n = 700)
Number of subjects: 1321

Group type: COMPARATOR
Intervention: Group III: ST segment depression in leads V1 to V3 equal to that in leads V4 to V6 (n = 162)
Number of subjects: 1321

Group type: COMPARATOR
Intervention: Group IV: Maximal ST depression in leads V4 to V6 (n = 113)
Number of subjects: 1321
Study: 1635361

Group type: EXPERIMENTAL
Intervention: Prostacyclin (Epoprostenol Wellcome or Chinoin) at a dose of 5 mg/kg/min intravenously in 5 infusions
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (0.1 M glycine buffer of pH 10.5)
Number of subjects: 30
Study: 6719511

Group type: EXPERIMENTAL
Intervention: Preoperative irradiation with 34.5 Gy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Only operated patients (control group)
Number of subjects: 0
Study: 30702303

Group type: EXPERIMENTAL
Intervention: Standardized positive feedback on speech
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Standardized neutral feedback on speech
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Public speaking task
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Recall after 5 minutes and after 1 week
Number of subjects: 122

Group type: COMPARATOR
Intervention: Nonanxious community controls
Number of subjects: 122
Study: 28851055

Group type: EXPERIMENTAL
Intervention: Telmisartan (80 mg once per day)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 25245928

Group type: EXPERIMENTAL
Intervention: ABM training (n = 27)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo (n = 27)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Assessment-only (n = 23)
Number of subjects: 77
Study: 23548052

Group type: EXPERIMENTAL
Intervention: Yoga classes for 8 weeks
Number of subjects: 20
Study: 21655743

Group type: EXPERIMENTAL
Intervention: Intense intermittent exercise
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Moderate continuous exercise
Number of subjects: 20

Group type: COMPARATOR
Intervention: No exercise (control)
Number of subjects: 20
Study: 18092355

Group type: EXPERIMENTAL
Intervention: Delayed extubation after 36 hr
Number of subjects: 86

Group type: COMPARATOR
Intervention: Immediate extubation
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Both groups (Delayed and Immediate extubation) with CTGI and lung protective strategy
Number of subjects: 86
Study: 16280353

Group type: EXPERIMENTAL
Intervention: Botulinum toxin treatment
Number of subjects: 2

Group type: COMPARATOR
Intervention: Orofacial dystonia (Meige's syndrome)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 2
Study: 14511870

Group type: EXPERIMENTAL
Intervention: Vaginal hysterectomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Total abdominal hysterectomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Laparoscopic hysterectomy
Number of subjects: 60
Study: 10922161

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash (used twice daily)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no chlorhexidine mouthwash)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups (Chlorhexidine and Control)
Number of subjects: 21
Study: 8824341

Group type: EXPERIMENTAL
Intervention: Apomorphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study: 1375820

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) for 1 week
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo for 1 week
Number of subjects: 30
Study: 6379629

Group type: EXPERIMENTAL
Intervention: Cimetidine therapy
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 105
Study: 29664853

Group type: EXPERIMENTAL
Intervention: FX006 (32 mg)
Number of subjects: 484

Group type: COMPARATOR
Intervention: Saline‐solution placebo
Number of subjects: 484
Study: 27235297

Group type: EXPERIMENTAL
Intervention: Provider and patient/caregiver focused intervention including operational guidelines, systematic training, peer review of antibiotic prescribing, health education to patient caregivers, printed educational materials, and educational videos.
Number of subjects: 25

Group type: COMPARATOR
Intervention: Usual care via clinical consultations (Control)
Number of subjects: 25
Study: 25496487

Group type: EXPERIMENTAL
Intervention: l-carnitine (12 g)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 23583604

Group type: EXPERIMENTAL
Intervention: Thalidomide 200 mg per day (including a 2 week run in of 100 mg per day) plus active supportive care
Number of subjects: 222

Group type: COMPARATOR
Intervention: Active supportive care alone
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Thalidomide 200 mg per day
Number of subjects: 222

Group type: COMPARATOR
Intervention: Active supportive care
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 222
Study: 20954285

Group type: EXPERIMENTAL
Intervention: Brown rice
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Taro
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Adlay
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Yam
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mung bean noodles
Number of subjects: 10

Group type: COMPARATOR
Intervention: Reference bread
Number of subjects: 10
Study: 17604958

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Permanent pacemaker (PPM)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 248
Study: 16373466

Group type: EXPERIMENTAL
Intervention: Interactive CD-ROM program on safe medication practices
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 12450908

Group type: EXPERIMENTAL
Intervention: Daily iron supplementation (1 dose of 60 mg Fe/d)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Weekly iron supplementation (2 doses of 60 mg Fe once weekly)
Number of subjects: 50
Study: 10510150

Group type: COMPARATOR
Intervention: Placebo antitussive preceded at 1 h by placebo inhibitor
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 30 mg oral DEX preceded at 1 h by placebo inhibitor (DEX30)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 60 mg oral DEX preceded at 1 h by placebo inhibitor (DEX60)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 30 mg oral DEX preceded at 1 h by 50 mg oral quinidine sulphate (QDEX30)
Number of subjects: 22
Study: 8834127

Group type: EXPERIMENTAL
Intervention: Standard treatment (prednisone 10-15 mg/day) plus supplementary home oxygen therapy (mean 16.4 h/day) for 4 years.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard treatment (prednisone 10-15 mg/day) without home oxygen therapy for 4 years.
Number of subjects: 18
Study: 2036669

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Propranolol and Metoprolol (higher doses)
Number of subjects: 58
Study: 7016223

Group type: COMPARATOR
Intervention: Alkeran (600 mg/m2 x 5 days every 6 weeks)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Alkeran
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Vinblastine, Thiotepa, Methotrexate and 5 Fu (VTMF)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Methotrexate, 5 Fu (CMF)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: CMF VP (Vincristine and Prednisone)
Number of subjects: 406
Study: 31033457

Group type: EXPERIMENTAL
Intervention: Theraband exercise group (TBG)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 27
Study: 30859955

Group type: EXPERIMENTAL
Intervention: ALKS 3831
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: OLZ
Number of subjects: 403

Group type: COMPARATOR
Intervention: PBO
Number of subjects: 403
Study: 29259196

Group type: EXPERIMENTAL
Intervention: Inhaled nitrous oxide (N2O)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (without inhaled nitrous oxide)
Number of subjects: 47
Study: 27069173

Group type: EXPERIMENTAL
Intervention: Pre-hydration with 15 mEq magnesium sulfate (Mg-hydration group)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Non-pre-hydration (non-Mg-hydration group)
Number of subjects: 74
Study: 24859114

Group type: EXPERIMENTAL
Intervention: Energy-restricted diets with varying glycemic load (GL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Energy-restricted diets with provided food for the first six months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Energy-restricted diets with self-selected food after six months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Energy-restricted diets with lesser amounts of weight loss
Number of subjects: 0
Study: 22609644

Group type: EXPERIMENTAL
Intervention: Continuous spinal anesthesia (CSA)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Propofol target-controlled infusion (TCI)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sevoflurane (SEVO)
Number of subjects: 45
Study: 19248130

Group type: EXPERIMENTAL
Intervention: Initial combination therapy with infliximab
Number of subjects: 508

Group type: COMPARATOR
Intervention: Initial combination therapy with prednisone
Number of subjects: 508

Group type: COMPARATOR
Intervention: Step-up combination therapy
Number of subjects: 508

Group type: COMPARATOR
Intervention: Sequential monotherapy
Number of subjects: 508
Study: 17884605

Group type: EXPERIMENTAL
Intervention: Self-administered SCREEN II
Number of subjects: 134

Group type: COMPARATOR
Intervention: Telephone-administered SCREEN II
Number of subjects: 134
Study: 15066083

Group type: EXPERIMENTAL
Intervention: Interventions on Frailty recommendations for screening, recruiting, evaluating, and retaining frail older persons in clinical trials.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strategies to improve retention and compliance in clinical trials.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estimation of cost and sample size for clinical trials.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Additional research needs identified.
Number of subjects: 0
Study: 11741732

Group type: EXPERIMENTAL
Intervention: Ethylenediaminetetraacetic acid (EDTA) for 30s
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Phosphoric acid gel for 60s
Number of subjects: 110

Group type: COMPARATOR
Intervention: No etching
Number of subjects: 110
Study: 10443656

Group type: COMPARATOR
Intervention: HP FSH (150 IU/day) alone (group A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: HP FSH (150 IU/day) combined with hCG (50 IU/day) (group B)
Number of subjects: 20
Study: 7798679

Group type: EXPERIMENTAL
Intervention: Towne vaccine (approximately 500 pfu)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: COMPARATOR
Intervention: Naturally seropositive subjects
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Towne vaccine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Wild type infection
Number of subjects: 80
Study: 11527124

Group type: EXPERIMENTAL
Intervention: Bisoprolol (10 mg once a day for 8 weeks, dosage doubled after 4 weeks if DBP > 90 mm Hg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Acebutolol (400 mg once a day for 8 weeks, dosage doubled after 4 weeks if DBP > 90 mm Hg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Bisoprolol
Number of subjects: 46

Group type: COMPARATOR
Intervention: Acebutolol
Number of subjects: 46
Study: 372255

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthrinse
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 29
Study: 30849925

Group type: EXPERIMENTAL
Intervention: Internet-based community reinforcement approach (CRA) plus contingency management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard outpatient care
Number of subjects: 0
Study: 28327174

Group type: EXPERIMENTAL
Intervention: 6-h group-based intervention for students, two 2-h training workshops for teachers, provision of light PA equipment in classrooms.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Acceptability ratings of sessions for students (M = 6.29, scale 1-7).
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Objective measures of PA and SB (7-day accelerometry) conducted at T1, T3, and T4.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Self-reported PA and sitting measured at baseline (T1), mid-intervention (T2), post-intervention (T3), and 6 months after baseline (T4).
Number of subjects: 33
Study: 25471197

Group type: EXPERIMENTAL
Intervention: 4 mg/kg caffeine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coffee (expectation of caffeine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bitter lemon soda (no expectation of caffeine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine (expected and administered)
Number of subjects: 0
Study: 23429905

Group type: EXPERIMENTAL
Intervention: Alcohol consumption (300 mL)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Dräger DrugTest 5000
Number of subjects: 17

Group type: COMPARATOR
Intervention: DrugTest 5000
Number of subjects: 17
Study: 22013793

Group type: EXPERIMENTAL
Intervention: Xinluotong Tablet (XLTT), four tablets each time, three times a day
Number of subjects: 240

Group type: COMPARATOR
Intervention: Yangxinshi Tablet (YXST), three tablets each time, three times a day
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Xinluotong Tablet (XLTT)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Yangxinshi Tablet (YXST)
Number of subjects: 240
Study: 19242286

Group type: EXPERIMENTAL
Intervention: peginterferon alpha‐2a alone or with ribavirin
Number of subjects: 114
Study: 17938390

Group type: EXPERIMENTAL
Intervention: Aspirin, 100 mg
Number of subjects: 39876

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39876
Study: 14607578

Group type: EXPERIMENTAL
Intervention: GnRH agonist (leuprolide acetate; 1 mg/d, SC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA; 20 mg/d)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MPA during second 12 weeks (protocol B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10666141

Group type: EXPERIMENTAL
Intervention: Microdialysis with probes inserted in the vastus lateralis muscle measuring interstitial K(+) concentrations
Number of subjects: 0
Study: 8653729

Group type: EXPERIMENTAL
Intervention: Quinidine (330 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1613709

Group type: EXPERIMENTAL
Intervention: Tidal knee irrigation
Number of subjects: 77
Study: 6089555

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg daily
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 3094059

Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.65 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clonidine (200 micrograms)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31286252

Group type: EXPERIMENTAL
Intervention: Faculty-led instruction
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Peer tutor-led instruction
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Holography-augmented instruction
Number of subjects: 44

Group type: COMPARATOR
Intervention: Overall comparison
Number of subjects: 44

Group type: COMPARATOR
Intervention: Overall program evaluation
Number of subjects: 44
Study: 29896798

Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion to achieve target MAP of 75 mm Hg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion to achieve target MAP of 90 mm Hg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Norepinephrine infusion to achieve target MAP of 60 mm Hg
Number of subjects: 10
Study: 25730591

Group type: EXPERIMENTAL
Intervention: Dance Movement Therapy (DMT) during radiotherapy (6 sessions at 90 minutes each)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Dance Movement Therapy (DMT) after radiotherapy (1 to 2 months post-treatment)
Number of subjects: 104
Study: 24668261

Group type: EXPERIMENTAL
Intervention: Harp therapy during embryo transfer
Number of subjects: 181

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Harp therapy
Number of subjects: 181
Study: 23412077

Group type: EXPERIMENTAL
Intervention: Intensive glycemia control
Number of subjects: 8929

Group type: COMPARATOR
Intervention: Standard glycemia control
Number of subjects: 8929

Group type: EXPERIMENTAL
Intervention: Intensive participants who never took insulin or TZD
Number of subjects: 8929

Group type: EXPERIMENTAL
Intervention: Intensive participants who began insulin or TZD after enrollment
Number of subjects: 8929
Study: 19941160

Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg) for 12 weeks followed by Anastrozole (1 mg) for 12 weeks
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg) for 12 weeks followed by Letrozole (2.5 mg) for 12 weeks
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Tamoxifen (after 6 months of AI therapy)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Prior Tamoxifen therapy
Number of subjects: 94
Study: 17964821

Group type: EXPERIMENTAL
Intervention: Conventional stripping
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Cryostripping
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 160
Study: 16096715

Group type: EXPERIMENTAL
Intervention: Exercise group (EG) - low-volume high-resistance strength training and high-impact aerobics, supplemented with calcium and vitamin D.
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (CG) - non-training, supplemented with calcium and vitamin D.
Number of subjects: 78
Study: 12795585

Group type: EXPERIMENTAL
Intervention: Prevention program for depressive and anxious symptoms
Number of subjects: 189

Group type: COMPARATOR
Intervention: Usual health education classes (Control)
Number of subjects: 189
Study: 11190602

Group type: EXPERIMENTAL
Intervention: Nonparametric tests for stratum interaction with covariates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonparametric tests for stratum interaction with baseline hazard functions
Number of subjects: 0
Study: 9033825

Group type: EXPERIMENTAL
Intervention: Preoperative ilio-hypogastric nerve block in 21 patients
Number of subjects: 42

Group type: COMPARATOR
Intervention: No ilio-hypogastric nerve block in 21 patients (Control)
Number of subjects: 42
Study: 1793238

Group type: EXPERIMENTAL
Intervention: HeNe laser treatment (wave-length, 632.8 nm; beam power, 6 mW; continuous emission, energy density, 4 J/cm2)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo HeNe laser treatment
Number of subjects: 46